MetLife Reports 2025 Results, Outlines Strong 2026-2029 Targets, and Details Strategic Acquisition & Share Buybacks
MET sits 20% above its 52-week low of $65.21.
Summary
MetLife filed its 2025 10-K, detailing strong financial results, a significant acquisition, substantial share repurchases, and positive multi-year financial targets, despite minor regulatory headwinds.
Key Events · Earnings and Guidance · MET
-
Strong 2025 Adjusted Earnings
Adjusted earnings available to common shareholders increased to $5.9 billion in 2025, up from $5.8 billion in 2024, demonstrating continued operational strength.
-
Positive Multi-Year Financial Targets
The company maintains near-term annual targets for 15%-17% adjusted return on equity and double-digit adjusted earnings per share growth, alongside a commitment to generate approximately $25.0 billion in free cash flow over the 2025-2029 period.
-
Significant Share Repurchase Program
MetLife repurchased approximately $430 million of common stock in Q4 2025, with $2.1 billion remaining under its $3.0 billion authorization announced in April 2025, indicating a strong capital return strategy.
-
Finalized PineBridge Investments Acquisition
The acquisition of PineBridge Investments was completed on December 30, 2025, for $885 million, enhancing MetLife Investment Management's scale and global product offerings.
Analysis · MET · Finance
MetLife's 2025 Annual Report provides comprehensive financial results and robust forward-looking guidance, reinforcing a positive outlook for the company. The detailed targets for adjusted EPS growth, return on equity, and free cash flow over the next five years offer investors clear performance expectations. The significant share repurchase activity in Q4 2025 and the substantial remaining authorization signal a strong commitment to returning capital to shareholders. Additionally, the finalized acquisition of PineBridge Investments is a strategic move to bolster the asset management segment. While a new tax law in Mexico presents a minor headwind, the overall financial health and strategic initiatives outlined in this filing are highly material for investors.
At the time of this filing, MET was trading at $78.10 on NYSE in the Finance sector, with a market capitalization of approximately $51.5B. The 52-week trading range was $65.21 to $87.39. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.